NCT00343356View on ClinicalTrials.gov

Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder

PHASE2CompletedINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

June 30, 1996

Study Completion Date

July 31, 2003

Conditions

Bladder Neoplasms

Interventions

DRUG

Trement

All Listed Sponsors

lead

LanZhou University

OTHER

NCT00343356 - Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder | Biotech Hunter | Biotech Hunter